Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

14.3%

1 terminated/withdrawn out of 7 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 3 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

N/A

2(66.7%)

Phase 1

1(33.3%)

3Total

N/A(2)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT06268405Not ApplicableRecruiting

Positron Emission Mammography and Liquid Biopsy in Women With High-risk Breast Screenings

Role: collaborator

NCT04863924Active Not Recruiting

Accelerating Lung Cancer Diagnosis Through Liquid Biopsy

Role: collaborator

NCT06390657Withdrawn

Radiotherapy Treatment Planning Comparison Using SBRT-PATHY (Photons) Versus CARBON-PATHY for Unresectable Bulky Tumors

Role: collaborator

NCT05254782Recruiting

Using ctDNA to Detect Minimal Residual Disease After Lung Cancer Resection

Role: collaborator

NCT01305915Not ApplicableCompleted

Getting Back on Track: An Educational Group for Women With Breast Cancer

Role: collaborator

NCT01954316Phase 1Completed

A Study of CFI-400945 Fumarate in Patients With Advanced Cancer

Role: collaborator

NCT03558165Completed

Lung Cancer Next Generation Sequencing Using the Oncomine Comprehensive Assay

Role: collaborator

All 7 trials loaded